01:38 , Sep 2, 2015 |  BC Extra  |  Company News

Amgen, Novartis enter risk-sharing CNS deal

Amgen Inc. (NASDAQ:AMGN) and Novartis AG (NYSE:NVS; SIX:NOVN) will collaborate to co-develop and co-commercialize candidates in Alzheimer's disease and migraine. The companies said they will combine beta-site APP-cleaving enzyme (BACE) inhibitor programs to treat AD....
03:14 , Dec 20, 2014 |  BC Extra  |  Clinical News

Roche down on Phase III setbacks

Roche (SIX:ROG; OTCQX:RHHBY) fell CHF18.30 to CHF270.40 on Friday after reporting disappointing data from a Phase III trial of breast cancer drug Kadcyla ado-trastuzumab emtansine and discontinuing a Phase III study of gantenerumab to treat...
00:55 , Jul 17, 2014 |  BC Extra  |  Top Story

Crenezumab misses in AD Phase IIs

Crenezumab from the Genentech unit of Roche (SIX:ROG; OTCQX:RHHBY) missed the primary and secondary endpoints in two Phase II trials to treat Alzheimer's disease. Genentech said it is "premature" to discuss development plans for the...
00:46 , Jul 16, 2014 |  BC Extra  |  Company News

Novartis, Banner partner on Alzheimer's trial

Novartis AG (NYSE:NVS; SIX:NOVN) partnered with not-for-profit Banner Alzheimer's Institute (BAI) (Phoenix, Ariz.) to evaluate two of the pharma's compounds in cognitively healthy adults at risk of developing symptoms of Alzheimer's disease because they have...